Figure 4.

Effects of DAGL inhibitors on whole gut transit (WGT). Mice were treated with scopolamine (A, 0.5 mg·kg⁻¹, i.p.) or loperamide (B, 0.5 mg·kg⁻¹, i.p.) that significantly reduced WGT (increasing the transit time) in the WT or the CB₁^−/− mice. Orlistat (1 mg·kg⁻¹, i.p.) or OMDM-188 (1 mg·kg⁻¹, i.p.) reversed the effect of scopolamine and loperamide on WGT in the WT but not the CB₁^−/− mice. Note that neither orlistat nor OMDM-188 had any effect on transit when given alone in untreated animals. n = 4–12 mice per group; F (degrees of freedom) for interaction of panel A: F (3,55) = 11.15, P < 0.001 and panel B: F (3,36) = 4.32, P < 0.05); two-way anova; Bonferroni post hoc test. **P < 0.01, ***P < 0.001 compared with vehicle in WT or CB₁^−/− mice; #P < 0.05, ###P < 0.001, compared with scopolamine or loperamide in WT mice.